BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31709722)

  • 1. Bone marrow niches in myeloid neoplasms.
    Kitagawa M; Kurata M; Onishi I; Yamamoto K
    Pathol Int; 2020 Feb; 70(2):63-71. PubMed ID: 31709722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
    Miller LH; Qu CK; Pauly M
    Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bone's Role in Myeloid Neoplasia.
    Kazianka L; Staber PB
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.
    Flores-Figueroa E; Gratzinger D
    Int J Mol Sci; 2016 Apr; 17(4):553. PubMed ID: 27089321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid malignancies and the microenvironment.
    Korn C; Méndez-Ferrer S
    Blood; 2017 Feb; 129(7):811-822. PubMed ID: 28064238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the role of the microenvironment in MDS?
    Calvi LM; Li AJ; Becker MW
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies.
    Behrmann L; Wellbrock J; Fiedler W
    Expert Opin Ther Targets; 2020 May; 24(5):451-462. PubMed ID: 32188313
    [No Abstract]   [Full Text] [Related]  

  • 15. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
    Aanei CM; Catafal LC
    Cytometry A; 2018 Jul; 93(9):916-928. PubMed ID: 30211968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
    Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
    Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow neoplastic niche in leukemia.
    Azizidoost S; Babashah S; Rahim F; Shahjahani M; Saki N
    Hematology; 2014 Jun; 19(4):232-8. PubMed ID: 23905984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
    Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
    Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.